Renaissance Technologies (RenTech)'s TGTX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 679,300 shares of TG Therapeutics, Inc. (TGTX) worth $37.32 M, representing 0.05% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 33 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in TGTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2019, adding 1.07 M shares. Largest reduction occurred in Q3 2020, reducing 1.06 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s TG Therapeutics (TGTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly TG Therapeutics (TGTX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +338,400 | Add 99.27% | 679,300 | $54.94 |
| Q1 2026 | +340,900 | New Buy | 340,900 | $33.22 |
| Q2 2025 | -168,594 | Sold Out | 0 | $0.00 |
| Q1 2025 | +168,594 | New Buy | 168,594 | $39.43 |
| Q3 2024 | -309,371 | Sold Out | 0 | $0.00 |
| Q2 2024 | -531,229 | Reduce 63.20% | 309,371 | $17.79 |
| Q1 2024 | +1,400 | Add 0.17% | 840,600 | $15.21 |
| Q4 2023 | -537,262 | Reduce 39.03% | 839,200 | $17.08 |
| Q3 2023 | +840,262 | Add 156.71% | 1.38 M | $8.36 |
| Q2 2023 | +536,200 | New Buy | 536,200 | $0.02 |
| Q1 2023 | -99,100 | Sold Out | 0 | $0.00 |
| Q4 2022 | -80,100 | Reduce 44.70% | 99,100 | $0.01 |
| Q3 2022 | -1 M | Reduce 84.83% | 179,200 | $5.92 |
| Q2 2022 | +983,500 | Add 497.72% | 1.18 M | $4.25 |
| Q1 2022 | -51,600 | Reduce 20.71% | 197,600 | $9.51 |
| Q4 2021 | +249,200 | New Buy | 249,200 | $19.00 |
| Q3 2021 | -145,800 | Sold Out | 0 | $0.00 |
| Q2 2021 | +11,800 | Add 8.81% | 145,800 | $38.79 |
| Q1 2021 | -234,000 | Reduce 63.59% | 134,000 | $48.20 |
| Q4 2020 | +269,400 | Add 273.23% | 368,000 | $52.02 |
| Q3 2020 | -1.06 M | Reduce 91.47% | 98,600 | $26.76 |
| Q2 2020 | +643,600 | Add 125.75% | 1.16 M | $19.48 |
| Q1 2020 | -667,700 | Reduce 56.61% | 511,800 | $9.84 |
| Q4 2019 | +1.07 M | Add 984.16% | 1.18 M | $11.10 |
| Q3 2019 | -51,706 | Reduce 32.22% | 108,794 | $5.62 |
| Q2 2019 | +114,400 | Add 248.16% | 160,500 | $8.65 |
| Q1 2019 | -829,800 | Reduce 94.74% | 46,100 | $8.05 |
| Q4 2018 | +523,400 | Add 148.48% | 875,900 | $4.10 |
| Q3 2018 | +352,500 | New Buy | 352,500 | $5.60 |
| Q2 2015 | -19,399 | Sold Out | 0 | $0.00 |
| Q1 2015 | -138,482 | Reduce 87.71% | 19,399 | $15.46 |
| Q4 2014 | +146,682 | Add 1309.78% | 157,881 | $15.84 |
| Q3 2014 | +11,199 | New Buy | 11,199 | $10.63 |
Renaissance Technologies (RenTech)'s TG Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased TG Therapeutics, Inc. (TGTX) in Q3 2014, acquiring 11,199 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held TG Therapeutics, Inc. (TGTX) for 33 quarters since Q3 2014.
Renaissance Technologies (RenTech)'s largest addition to TG Therapeutics, Inc. (TGTX) was in Q4 2019, adding 1,179,500 shares worth $13.09 M.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 679,300 shares of TG Therapeutics, Inc. (TGTX), valued at approximately $37.32 M.
As of the Q2 2026 filing, TG Therapeutics, Inc. (TGTX) represents approximately 0.05% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in TG Therapeutics, Inc. (TGTX) was 1,376,462 shares, as reported at the end of Q3 2023.